Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-20
    E.g., 2018-10-20

Archive Search

Pages

11 results
5:20 PM, Nov 25, 2013  |  BC Extra | Clinical News

Cubist gains on Phase III data for ceftolozane/tazobactam

of market exclusivity if it is approved. Cubist has worldwide rights to ceftolozane (CXA-101), a cephalosporin antibiotic
5:31 PM, Jun 16, 2011  |  BC Extra | Clinical News

Cubist reports Phase II data

to treat nosocomial pneumonia in 2012. The product is a combination of CXA-101 , a cephalosporin antibiotic
5:58 PM, Jun 19, 2009  |  BC Extra | Clinical News

Ceftaroline meets Phase III endpoint

caused by bacteria who required treatment with IV antibiotics. Forest gained worldwide rights to the cephalosporin antibiotic
5:32 PM, Jun 19, 2008  |  BC Extra | Clinical News

Forest's ceftaroline meets cSSSI endpoint

II trials to treat complicated skin and skin structure infections (91.6% vs. 92.7%). Ceftaroline, a cephalosporin antibiotic
6:40 PM, Sep 14, 2007  |  BC Extra | Clinical News

Ceftobiprole meets Phase III CAP endpoint

comparator arms. BSLN granted Johnson & Johnson (JNJ) worldwide rights to the broad spectrum anti-MRSA cephalosporin antibiotic
5:59 PM, Jan 10, 2007  |  BC Extra | Clinical News

Ceftobiprole meets Phase III cSSSI endpoint

Gram-positive cSSSIs ( See BioCentury Extra, Thursday, March 02, 2006 ). The broad spectrum anti-MRSA cephalosporin antibiotic
6:08 PM, Aug 02, 2006  |  BC Extra | Clinical News

Cerexa reports ceftaroline Phase II data

vancomycin with or without aztreonam. Cerexa has exclusive worldwide rights to develop and commercialize the cephalosporin antibiotic
6:28 PM, May 17, 2006  |  BC Extra | Clinical News

Basilea, JNJ start ceftobiprole Phase III

trial for Gram-positive and -negative cSSSIs and another for hospital-acquired pneumonia. The broad spectrum anti-MRSA cephalosporin antibiotic
6:52 PM, Mar 02, 2006  |  BC Extra | Clinical News

Ceftobiprole meets Phase III cSSSI endpoint

pneumonia. Data for both trials are expected in the second half. The broad spectrum anti-MRSA cephalosporin antibiotic
12:00 AM, Feb 26, 2004  |  BC Extra | Clinical News

Cubist terminates CAB-175

CBST terminated development of CAB-175, a cephalosporin antibiotic, because of adverse events. The company said last May …

Pages